JP7437307B2 - ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１ - Google Patents

ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１ Download PDF

Info

Publication number
JP7437307B2
JP7437307B2 JP2020544565A JP2020544565A JP7437307B2 JP 7437307 B2 JP7437307 B2 JP 7437307B2 JP 2020544565 A JP2020544565 A JP 2020544565A JP 2020544565 A JP2020544565 A JP 2020544565A JP 7437307 B2 JP7437307 B2 JP 7437307B2
Authority
JP
Japan
Prior art keywords
cells
neo
cancer
antibody
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020544565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502416A5 (enExample
JP2021502416A (ja
Inventor
アーレン、フィリップ、エム．
ツァン、クウォン、ワイ．
Original Assignee
プレシジョン バイオロジックス、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレシジョン バイオロジックス、インコーポレイテッド filed Critical プレシジョン バイオロジックス、インコーポレイテッド
Publication of JP2021502416A publication Critical patent/JP2021502416A/ja
Publication of JP2021502416A5 publication Critical patent/JP2021502416A5/ja
Priority to JP2023181486A priority Critical patent/JP7712338B2/ja
Application granted granted Critical
Publication of JP7437307B2 publication Critical patent/JP7437307B2/ja
Priority to JP2025115696A priority patent/JP2025148435A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2020544565A 2017-11-03 2018-11-02 ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１ Active JP7437307B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023181486A JP7712338B2 (ja) 2017-11-03 2023-10-20 ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１
JP2025115696A JP2025148435A (ja) 2017-11-03 2025-07-09 ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762581380P 2017-11-03 2017-11-03
US62/581,380 2017-11-03
US201762592778P 2017-11-30 2017-11-30
US62/592,778 2017-11-30
PCT/US2018/059039 WO2019090134A1 (en) 2017-11-03 2018-11-02 Monoclonal antibody neo-201 for the treatment of human carcinomas

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023181486A Division JP7712338B2 (ja) 2017-11-03 2023-10-20 ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１

Publications (3)

Publication Number Publication Date
JP2021502416A JP2021502416A (ja) 2021-01-28
JP2021502416A5 JP2021502416A5 (enExample) 2021-12-02
JP7437307B2 true JP7437307B2 (ja) 2024-02-22

Family

ID=66332711

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020544565A Active JP7437307B2 (ja) 2017-11-03 2018-11-02 ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１
JP2023181486A Active JP7712338B2 (ja) 2017-11-03 2023-10-20 ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１
JP2025115696A Pending JP2025148435A (ja) 2017-11-03 2025-07-09 ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023181486A Active JP7712338B2 (ja) 2017-11-03 2023-10-20 ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１
JP2025115696A Pending JP2025148435A (ja) 2017-11-03 2025-07-09 ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１

Country Status (7)

Country Link
US (2) US11767367B2 (enExample)
EP (1) EP3735423A4 (enExample)
JP (3) JP7437307B2 (enExample)
CN (3) CN119587690A (enExample)
AU (2) AU2018360045B2 (enExample)
CA (1) CA3083467A1 (enExample)
WO (1) WO2019090134A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019221544B2 (en) * 2018-02-13 2025-07-10 Precision Biologics, Inc. Methods and compositions for targeting Treg cells
CN115678854A (zh) * 2021-07-29 2023-02-03 上海中医药大学 一种基因工程细胞及其制备方法和应用
CN119053622A (zh) * 2022-04-12 2024-11-29 盛禾(中国)生物制药有限公司 一种抗ceacam5和ceacam6抗体及其应用
CN116699135B (zh) * 2022-04-29 2025-11-07 中国医学科学院肿瘤医院 癌症免疫治疗靶标和诊断、预后预测生物标志物的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017521410A (ja) 2014-06-30 2017-08-03 アルター・バイオサイエンス・コーポレーション Ｉｌ−１５ベース分子及びその使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2585476A4 (en) * 2010-06-22 2014-01-22 Neogenix Oncology Inc ANTIGENS AND ANTIBODIES SPECIFIC TO COLON AND PANCREATIC CANCER
EP3336104A1 (en) * 2012-12-28 2018-06-20 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
WO2018218230A1 (en) * 2017-05-26 2018-11-29 Etubics Corporation Combination immunotherapies comprising il-15 superagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017521410A (ja) 2014-06-30 2017-08-03 アルター・バイオサイエンス・コーポレーション Ｉｌ−１５ベース分子及びその使用方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GEISLER, J.P. et al.，Gynecol Oncol，2016年，Vol. 141，p. 95-96
NEUMAN, M.K. et al.，Cancer Res，2016年，Vol. 76, No. 14, Suppl.，Abstract No. 1496
VIDARSSON, G. et al.，Front Immunol，2014年，Vol. 5, Article No. 520，pp. 1-17
ZELIGS, K. et al.，Cancer Res，2017年07月，Vol. 77, Issue 13, Suppl. ，Abstract No. 3025

Also Published As

Publication number Publication date
AU2025205420A1 (en) 2025-07-31
CN120860200A (zh) 2025-10-31
JP2024010054A (ja) 2024-01-23
JP7712338B2 (ja) 2025-07-23
US11767367B2 (en) 2023-09-26
JP2025148435A (ja) 2025-10-07
US20200362053A1 (en) 2020-11-19
EP3735423A1 (en) 2020-11-11
CN111670199A (zh) 2020-09-15
US20240101702A1 (en) 2024-03-28
CN119587690A (zh) 2025-03-11
WO2019090134A1 (en) 2019-05-09
CN111670199B (zh) 2025-06-17
JP2021502416A (ja) 2021-01-28
CA3083467A1 (en) 2019-05-09
AU2018360045A1 (en) 2020-05-21
EP3735423A4 (en) 2021-02-24
AU2018360045B2 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
CN113347994B (zh) 使用her3抗原结合分子治疗和预防癌症
CN112513095B (zh) Her3抗原结合分子
JP7712338B2 (ja) ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１
EP2050466B1 (en) Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
KR20200079511A (ko) Cd47 항원-결합 분자
KR20180133399A (ko) 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체
US20240400714A1 (en) Methods and compositions for targeting treg cells
Fantini et al. Preclinical characterization of a novel monoclonal antibody NEO-201 for the treatment of human carcinomas
US20150071931A1 (en) LM-Antibodies, Functional Fragments, LM-1 Target Antigen, and Methods for Making and Using Same
JP6939555B2 (ja) 癌の治療及び／又は予防用医薬組成物
HK40052624B (en) Treatment and prevention of cancer using her3 antigen-binding molecules
HK40052624A (en) Treatment and prevention of cancer using her3 antigen-binding molecules

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231024

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240209

R150 Certificate of patent or registration of utility model

Ref document number: 7437307

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150